Perspective Therapeutics, Inc. (CATX) AI Stock Analysis

Perspective Therapeutics, Inc., based in Seattle, Washington, specializes in developing precision-targeted alpha therapies (TAT) for treating cancer patients with metastatic disease across various tumor types. The company is advancing initial drug candidates VMT-a-NET and VMT01, both in Phase 1/2a clinical trials. VMT-a-NET targets unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors. Concurrently, VMT01 is being evaluated as a potential second-line therapy for patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics also maintains a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate [212Pb] VMT01 combined with nivolumab.

Revenue has declined from $5.4M in FY2022 to $884,000 in FY2025, representing a 5-year revenue CAGR of -39.4%. Operating margin dropped from -168.1% in FY2022 to -12846.6% in FY2025 as research and development expense expanded from $1.8M to $84.2M over the same period. Annual net losses increased from -$10.8M in FY2022 to -$103.1M in FY2025, with diluted EPS declining to -$1.41. For the trailing twelve months ended June 30, 2026, revenue totaled $409,000, operating margin stood at -36121.0%, and quarterly revenue growth declined 72.1% year-over-year.

As of June 30, 2026, Perspective Therapeutics reported $236.9M in cash and short-term investments alongside total debt of $4.0M, resulting in net cash of $232.9M. The company has a current ratio of 6.61 and a debt-to-equity ratio of 0.01 against shareholders' equity of $323.9M. In FY2025, capital expenditures were $12.7M, operating cash flow was -$82.5M, and free cash flow stood at -$95.2M. Over five years, the company's share count increased 421.0%.

At a last close of $2.17 on October 16, 2026, Perspective Therapeutics had a market cap of $247.7M and an enterprise value of $66.2M. The stock trades at a price-to-sales ratio of 605.6x and a forward P/E of 25.7x, compared to the median of its US-listed Healthcare peers of 4.1x and 17.3x, respectively. Its price-to-book ratio is 0.9x. Over the past year, shares fell 54.3%, underperforming the S&P 500 (SPY) return of 16.8%.

Wall Street coverage consists of 10 Strong Buy, 3 Buy, and 1 Hold ratings, with no Sell or Strong Sell ratings. The mean price target is $12.29, representing an upside of 466.2% versus the last close of $2.17. For the fiscal year ending December 31, 2026, analysts estimate an EPS of -$0.99 on revenue of $297,330. In the prior four quarters, the company beat EPS estimates twice. The next earnings date is scheduled for November 9, 2026.

This page is an AI-written research summary of Perspective Therapeutics, Inc. (CATX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: CATX income statement, CATX balance sheet, CATX key metrics, CATX analyst forecast, CATX chart. See the CATX stock overview for the latest quote and news.